The subject matter described herein relates to methods, systems and devices for holding, filling and/or delivering implantable drug delivery devices.
Implantable devices can be used to provide a therapeutic agent to one or more locations of a patient. The implant may have a reservoir for holding therapeutic agent, and a structure to retain the implant at a desired location of the patient. The agent can be released from the implant into the patient to provide a therapeutic benefit. After an amount of time, the amount of fluid released can be less than ideal, and the fluid of the implant may be replaced, refilled, or exchanged to provide additional amounts of therapeutic agent to extend the therapy. A drug delivery device may be implanted into a patient's eye for the delivery of drug to the eye in treating eye disease. U.S. Pat. No. 8,399,006, which is incorporated herein by reference, describes an example of an implantable drug delivery device for the eye.
There remains a need for devices and methods for filling implants with drug and for holding the implantable device during insertion of the device into the patient.
Implementations of the present disclosure provide methods, systems and devices for filling implants with drug and for holding the implantable device during insertion of the device into the patient. In many implementations, the methods, systems and devices provide for injection of a therapeutic agent into an implantable device prior to insertion. The implantable device can be manufactured and provided to a clinic without a therapeutic agent, such that the therapeutic agent can be placed in the implantable device in the clinic prior to insertion.
In one aspect, provided is an ocular implant system having an ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye. The system has a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell, the guide sleeve defining a proximal port into the central channel that is accessible from the proximal end of the shell. The system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve. The implant holder has a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder.
The system can further include a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve to fill the implant with one or more therapeutic agents. The guide sleeve can simultaneously detach from the shell and attach to the fill syringe when the fill syringe is inserted into the central channel. The guide sleeve can have at least one guide sleeve slot sized and shaped to receive a corresponding tab of the shell that projects into the at least one guide sleeve slot when the guide sleeve is positioned within the central channel. An edge of the guide sleeve slot can abut a distal end of the shell tab when in a locked first state. The fill syringe can have a needle assembly having an outer surface, and optionally the fill syringe can be pre-filled with the one or more therapeutic agents. Insertion of the fill syringe through the guide sleeve positioned within the central channel can cause contact between the outer surface of the needle assembly and an inner surface of the shell tab urging the shell tab to flex outward away from the guide sleeve slot into an unlocked second state wherein the edge of the guide sleeve slot no longer abuts the distal end of the shell tab.
A region of the guide sleeve can have a u-shaped slot forming a guide sleeve tab. The guide sleeve tab can have a free end that projects inwards towards a longitudinal axis of the guide sleeve positioned within the central channel. The fill syringe can have a first portion having a first outer diameter and a second portion having a second outer diameter. The first portion can be located distal to the second portion and the first outer diameter can be larger than the second outer diameter. Distal advancement of the fill syringe through the guide sleeve can cause the first portion of the fill syringe to abut against the free end of the guide sleeve tab and can urge the guide sleeve tab outward away from the longitudinal axis of the guide sleeve. Further distal advancement of the fill syringe through the guide sleeve can advance the first portion distal to the free end of the guide sleeve tab such that the free end flexes back inward toward the longitudinal axis and towards the smaller diameter second portion located proximal to the first portion. The free end of the guide sleeve tab can abut a proximal ledge of the first portion locking the guide sleeve to the fill syringe. The implant holder can have an interior configured to receive at least a portion of the needle assembly of the fill syringe.
The pair of graspers can extend substantially around the retention structure of the implant such that a fill port of the implant is available from within the interior of the implant holder. A first grasper of the pair of graspers can have a first protrusion and a second grasper of the pair of graspers can have a second protrusion. The first and second protrusions can be configured to be received within an indentation distal to the retention structure of the implant such that the retention structure is held within the interior of the implant holder and the reservoir extends distal to the implant holder.
The system can further include a handle member usable for inserting the implant into an eye. The implant holder can be configured to interchangeably couple with the carrier member and the handle member. The handle member can include an elongated proximal portion and a distal attachment portion. The distal attachment portion can releasably attach to the implant holder. The distal attachment portion of the handle member can be sized and shaped to be inserted through the central channel after the fill syringe and guide sleeve coupled to the fill syringe are removed from the shell. The distal attachment portion can include a first arm and a second arm. A proximal end region of the implant holder can have a pair of tabs formed by a pair of u-shaped slots. Each of the pair of tabs can have a projection on its inner surface. The first arm and the second arm can each have a recess on its outer surface. Each of the recesses can be configured to receive the projections when the first and second arms are inserted through the interior of the implant holder.
The handle member can further include an actuator configured to detach the implant from the implant holder. When the actuator is in a first state, the pair of graspers can be positioned adjacent one another and surround the implant. When the actuator is in a second state, the pair of graspers can be urged away from one another and release the implant. The actuator can include an actuator element, a spring-held slider member, and a pair of arms. The actuator element can have a projection extending from a lower surface and have a ramped surface. Movement of the actuator element towards the upper surface of the handle can cause the ramped surface to slide against a corresponding ramped surface of the slider member urging the slider member in a proximal direction relative to the pair of arms. The slider member can have a forked region interfaced with the pair of arms such that proximal movement of the slider member causes the pair of arms to open in a scissor-like movement. Opening the pair of arms can urge the pair of graspers away from one another releasing the implant held therebetween.
The central channel can terminate at a window extending through a distal end region of the shell. The pair of graspers can secure the implant within the window. The implant can have an elongate axis extending through a center of the implant from a proximal end to the distal end of the implant. The elongate axis of the implant can be concentric with an elongate axis of the central channel. A proximal end of the guide sleeve can be relatively flush with the proximal end of the shell. A proximal end of the guide sleeve can extend a distance beyond the proximal end of the shell. The proximal end of the guide sleeve can incorporate a gripping element. The gripping element can have an ergonomic size and shape that facilitates grasping by a user. The guide sleeve can have a generally cylindrical shape. The guide sleeve can have a c-shaped cross section such that a first side of the guide sleeve is cylindrical and a second side of the guide sleeve is discontinuous. The discontinuous second side of the guide sleeve can align with the first side of the shell and the central channel.
In an interrelated aspect, provided is an ocular implant handling system having a carrier member. The carrier member has a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. The carrier member has a guide sleeve removably attached within at least a first region of the central channel of the shell. The guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell. The carrier member has an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve. The implant holder has a pair of graspers adapted to releasably secure an implant at a distal end of the implant holder.
The handle member can be usable for inserting an implant into an eye. The system can further include an ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye.
The system can further include a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve. The guide sleeve can simultaneously detach from the shell and attach to the fill syringe when the fill syringe is inserted into the central channel. The guide sleeve can have at least one guide sleeve slot sized and shaped to receive a corresponding tab of the shell that projects into the at least one guide sleeve slot when the guide sleeve is positioned within the central channel. An edge of the guide sleeve slot can abut a distal end of the shell tab when in a locked first state. The fill syringe can have a needle assembly having an outer surface. Insertion of the fill syringe through the guide sleeve positioned within the central channel can cause contact between the outer surface of the needle assembly and an inner surface of the shell tab urging the shell tab to flex outward away from the guide sleeve slot into an unlocked second state wherein the edge of the guide sleeve slot no longer abuts the distal end of the shell tab. A region of the guide sleeve can have a u-shaped slot forming a guide sleeve tab. The guide sleeve tab can have a free end that projects inwards towards a longitudinal axis of the guide sleeve positioned within the central channel.
The fill syringe can have a first portion having a first outer diameter and a second portion having a second outer diameter. The first portion can be located distal to the second portion and the first outer diameter can be larger than the second outer diameter. Distal advancement of the fill syringe through the guide sleeve can cause the first portion of the fill syringe to abut against the free end of the guide sleeve tab and urge the guide sleeve tab outward away from the longitudinal axis of the guide sleeve. Further distal advancement of the fill syringe through the guide sleeve can advance the first portion distal to the free end of the guide sleeve tab such that the free end flexes back inward toward the longitudinal axis and towards the smaller diameter second portion located proximal to the first portion. The free end of the guide sleeve tab can abut a proximal ledge of the first portion locking the guide sleeve to the fill syringe.
The implant holder can have an interior configured to receive at least a portion of the needle assembly of the fill syringe. The pair of graspers can extend substantially around the retention structure of the implant such that a fill port of the implant is available from within the interior of the implant holder. A first grasper of the pair of graspers can have a first protrusion and a second grasper of the pair of graspers can have a second protrusion. The first and second protrusions can be configured to be received within an indentation distal to the retention structure of the implant such that the retention structure is held within the interior of the implant holder and the reservoir extends distal to the implant holder.
The handle member can include an elongated proximal portion and a distal attachment portion. The distal attachment portion can releasably attach to the implant holder. The distal attachment portion of the handle member can be sized and shaped to be inserted through the central channel after the fill syringe and guide sleeve coupled to the fill syringe are removed from the shell. The distal attachment portion can include a first arm and a second arm. A proximal end region of the implant holder can have a pair of tabs formed by a pair of u-shaped slots. Each of the pair of tabs can have a projection on its inner surface. The first arm and the second arm can each have a recess on its outer surface. Each of the recesses can be configured to receive the projections when the first and second arms are inserted through the interior of the implant holder.
The handle member can further include an actuator configured to detach the implant from the implant holder. When the actuator is in a first state, the pair of graspers can be positioned adjacent one another and surround the implant. When the actuator is in a second state, the pair of graspers can be urged away from one another and release the implant. The actuator can include an actuator element, a spring-held slider member, and a pair of arms. The actuator element can have a projection extending from a lower surface and having a ramped surface. Movement of the actuator element towards the upper surface of the handle can cause the ramped surface to slide against a corresponding ramped surface of the slider member urging the slider member in a proximal direction relative to the pair of arms. The slider member can have a forked region interfaced with the pair of arms such that proximal movement of the slider member causes the pair of arms to open in a scissor-like movement. Opening the pair of arms can urge the pair of graspers away from one another releasing an implant held therebetween.
The central channel can terminate at a window extending through a distal end region of the shell. The pair of graspers can secure an implant within the window. An implant can have an elongate axis extending through a center of the implant from a proximal end to the distal end of the implant. The elongate axis of the implant can be concentric with an elongate axis of the central channel. A proximal end of the guide sleeve can be relatively flush with the proximal end of the shell. A proximal end of the guide sleeve can extend a distance beyond the proximal end of the shell. The proximal end of the guide sleeve can incorporate a gripping element. The gripping element can have an ergonomic size and shape that facilitates grasping by a user. The guide sleeve can have a generally cylindrical shape. The guide sleeve can have a c-shaped cross section such that a first side of the guide sleeve is cylindrical and a second side of the guide sleeve is discontinuous. The discontinuous second side of the guide sleeve can align with the first side of the shell and the central channel.
In an interrelated aspect, provided is an ocular implant handling and delivery system. The system includes a handle member usable for inserting an ocular implant into an eye having an elongated proximal portion and a distal attachment portion. The system includes a carrier member having a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell. The guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell. The system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve. The implant holder has a pair of graspers adapted to releasably secure the ocular implant at a distal end of the implant holder. The implant holder is configured to interchangeably couple with the carrier member and the handle member.
The system can further include the ocular implant. The ocular implant can include a retention structure and a reservoir sized and can be shaped to be inserted at least partially into an eye such that the ocular implant can deliver a drug from the reservoir into the eye.
In an interrelated aspect, provided is an ocular implant handling and filling system. The system includes a carrier member having a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell. The guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell. The system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve. The implant holder has a pair of graspers adapted to releasably secure an ocular implant at a distal end of the implant holder. The system includes a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve.
The system can further includes the ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye. The system can further include a handle member usable for inserting an ocular implant into an eye. The handle member can include an elongated proximal portion and a distal attachment portion. The implant holder can be configured to interchangeably couple with the carrier member and the handle member.
In an interrelated aspect, provided is a handling and filling system having a carrier member. The carrier member includes a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. The carrier member includes a guide sleeve removably attached within at least a first region of the central channel of the shell. The guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell. The system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve. The implant holder has a pair of graspers adapted to releasably secure an implant at a distal end of the implant holder. The system includes a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve. The system includes a handle member usable for inserting the implant into an eye. The handle member includes an elongated proximal portion and a distal attachment portion. The implant holder is configured to interchangeably couple with the carrier member and the handle member.
The system can further include the ocular implant. The ocular implant can include a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the ocular implant can deliver a drug from the reservoir into the eye.
In an interrelated aspect, provided is a fill syringe sized and shaped to insert through a region of a carrier member holding an ocular implant. The fill syringe is configured to inject one or more therapeutic agents from the fill syringe into a reservoir of the ocular implant.
The carrier member can include a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. The carrier member can include a guide sleeve removably attached within at least a first region of the central channel of the shell. The guide sleeve can define a proximal port into the central channel that is accessible from the proximal end of the shell. A portion of the fill syringe can lock with a portion of the guide sleeve when the fill syringe is inserted through the central channel of the shell. Withdrawal of the fill syringe from the carrier member can remove the guide sleeve from the shell. The fill syringe can be pre-filled with the one or more therapeutic agents.
The above-noted aspects and features may be implemented in systems, apparatus, and/or methods, depending on the desired configuration. The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims.
In the drawings,
Described herein are methods, devices and systems for easily, reproducibly, and safely filling an ocular implant with a material, such as a drug, and inserting the implant into a patient, such as a patient's eye. Although specific reference is made to placement of devices in the eye, systems described herein can be used with many devices used in locations other than the eye, such as in orthopedic, dental, intraluminal and transdermal locations. The systems and methods described herein are well suited for use with many drug delivery devices, such as refillable diffusion based devices, and can be exceptionally well suited for diffusion devices having a porous drug release structure configured for extended release in which the porous structure inhibits flow of fluid during exchange.
A portion of the carrier member 105 can guide and properly align a cannula or needle 210 of the syringe 205 with the fill port of the implant 110. The syringe 205 can interdigitate with this portion of the carrier member 105 and lock into it such that when the syringe 205 is removed, for example, after filling the implant 110 with the drug from the syringe 205, the syringe 205 and this portion of the carrier member 105 locked onto the syringe can be withdrawn together. As will be described in more detail below, once the fill syringe 205 is removed (e.g. after the implant 110 is filled with drug), the handle member 115 can be inserted into the carrier member 105 and used to remove the implant 110 from the carrier member 105. The handle member 115 and the carrier member 105 can interchangeably couple to the implant 110. The handle member 115 can be coupled to the carrier member 105 in a manner that attaches the implant 110 to the handle member 115 and detaches the implant 110 from the carrier member 105. The handle member 115 can then be used to position the implant 110 and insert the implant 110 into an eye. Each of these features will be described in more detail below. It should be appreciated that the implant 110 can be pre-filled and stored within the carrier member 105. Alternatively, the implant 110 can be stored within the carrier member 105 while empty and filled prior to implantation in the eye, such as using a pre-filled syringe. It should also be appreciated that the implant 110 can be filled after implantation in the eye.
Generally, the implant 110 to be used with the system 100 described herein can include an internal reservoir. The reservoir can be a rigid-walled reservoir having a fixed volume. Alternatively, one or more of the reservoir walls can be configured to expand such that the reservoir volume changes depending on a fill status of the implant 110. The implant 110 can include a proximal retention structure 305 and an indentation 307 or narrowed region that is sized smaller than the retention structure 305. The indentation 307 can also be sized smaller than a shoulder region extending distal to the indentation 307. The indentation 307 can be sized to fit in an elongate incision. The proximal retention structure 305 can include an access port having a penetrable region. For example, the proximal retention structure 305 can include or be covered by a penetrable barrier or septum structure such that the reservoir can be filled with a material. One or more outlets can be positioned in fluid communication with the reservoir of the implant 110 such that therapeutic agent in the reservoir can be delivered to the patient. The one or more outlets can incorporate a porous structure including one or more of many porous structures such as sintered material, openings in a non-permeable material, openings having a size and number to release therapeutic agent at an intended rate, a plurality of holes etched in a material, a semi-permeable membrane, or nano-channels, for example. It should be appreciated that the configuration of implant 110 that can used with the system 100 described herein can vary. The systems described herein can be used with or incorporate features of devices described in U.S. Pat. No. 8,399,006, entitled “Posterior Segment Drug Delivery”; U.S. Pat. No. 8,905,963, entitled “Injector Apparatus and Method for Drug Delivery;” and U.S. Publication No. 2015/0080846, entitled “Insertion and Removal Methods and Apparatus for Therapeutic Devices,” the entire disclosures of which are incorporated herein by reference.
As best shown in
The shell 101 of the carrier member 105 can include a central channel 103 extending at least partially through an upper surface of a first side, such as its front side 107, from a proximal end 108 of the carrier member 105 towards a distal end region 109 of the carrier member 105 along a longitudinal axis. The central channel 103 can terminate at an opening or window 111 extending through a distal end region 109 of the shell 101. The implant 110 can be positioned by the implant holder 125 within the window 111. The shell 101 of the carrier member 105 can be generally ergonomically shaped such that a user can hold the carrier member 105 in one hand positioned around the underside of the carrier member 105. The central channel 103 can be available and readily visible on the front side 107 of the carrier member 105. The shell 101 of the carrier member 105 can include one or more textured regions 112 or indentations on its external surface to improve a user's grip on the carrier member 105 during use.
It should be appreciated that reference herein to terms such as “upper,” “lower,” “upwards,” “downwards,” “front,” “back,” “proximal,” “distal” are used herein for orientation from one point of view of a user operating the systems described herein and are not intended to be limiting.
The implant 110 can have an elongate axis extending through a center of the implant 110 from the proximal-most end to the distal-most end of the implant 110. The system 100 (and/or each of the components of the system) can also have an elongate axis that is concentric with the elongate axis of the implant 110 forming a longitudinal axis A with which each of the components of the system 100 are substantially aligned. When the implant 110 is held by the implant holder 125 within the carrier member 105, the elongate axis of the implant 110 can be aligned substantially with the longitudinal axis A of the system and the syringe 205 can be inserted substantially along the longitudinal axis A such that the needle 211 penetrates an upper surface of the implant 110. It should be appreciated that the syringe 205 can interdigitate within the central channel 103 along the longitudinal axis A or, in other implementations, can be inserted at an angle to the longitudinal axis A.
As mentioned, the carrier member 105 can include the guide sleeve 120 that can be removably attached within at least a region of the slot of the shell 101. The guide sleeve 120 can define a proximal port 113 into the central channel 103 of the shell 101 that allows for access to the slot from a proximal end of the shell 101. The guide sleeve 120 can help to ensure proper alignment between the syringe 205 and the implant 110 such that a needle 211 of the syringe 205 inserts through a septum or fill port of the implant 110. The guide sleeve 120 can provide guiding alignment during insertion of the syringe 205 through the port 113 into the central channel 103 towards the implant 110 mounted within the implant holder 125 of the carrier member 105.
The configuration of the guide sleeve 120 can vary. The guide sleeve 120 can have a length such that it extends a distance between the proximal end 108 of the shell 101 or central channel 103 and a distal region of the central channel 103. The guide sleeve 120 can be relatively flush with a proximal end 108 of the shell 101 (see
In some implementations, the guide sleeve 120 can have a generally cylindrical shape. The guide sleeve 120 can be a generally cylindrical element having an overall c-shaped cross section such that the underside or back side of the guide sleeve 120 is cylindrical and the front side of the guide sleeve 120 is slotted or discontinuous (see
As mentioned above and as best shown in
The distal opening of the reservoir 215 can be in fluid communication with a needle assembly 210 coupled to the syringe by a luer 255 (see
As mentioned above, the guide sleeve 120 can be removably attached from within the central channel 103 of the shell 101. The shell 101 and/or the guide sleeve 120 can include a locking mechanism that reversibly secures the guide sleeve 120 to the shell 101. The locking mechanism can be released, for example, upon insertion of the syringe 205 as will be described in more detail below. After the syringe 205 has been inserted into the guide sleeve 120 positioned within the central channel 103 of the shell 101 such as to inject drug into the implant 110, the locking mechanism between the guide sleeve 120 and the shell 101 can unlock. The guide sleeve 120 can release from the shell 101 and lock onto the syringe 205 such that both the guide sleeve 120 and the syringe 205 can be removed from the shell 101 upon withdrawal of the syringe 205 from the implant 110. The locking mechanism can simultaneously release the guide sleeve 120 from the shell 101 and lock the guide sleeve 120 onto a region of the syringe 205. When the syringe 205 is inserted into the guide sleeve 120, which can be in locked engagement with the shell 101 of the carrier member 105, the locking mechanism holding the guide sleeve 120 onto the syringe 205 can be activated or locked and the locking mechanism locking the guide sleeve 120 to the shell 101 can be deactivated or unlocked. The respective locking mechanisms can activate/deactivate in a simultaneous or step-wise manner. Once the switch in engagement occurs (i.e. locked engagement between the guide sleeve 120 and the shell 101 to an unlocked state and unlocked engagement of the syringe 205 and the guide sleeve 120 to a locked state), the syringe 205 can then be removed from the carrier member 105 with the guide sleeve 120 secured to the syringe 205.
The locking mechanism between the shell 101 and the guide sleeve 120 can include one or more corresponding slots and tabs providing a fixed, but reversible coupling between the shell 101 and the guide sleeve 120. In one implementation and as best shown in
This same act of inserting the syringe 205 distally through the guide sleeve 120 releasing the locked engagement between the guide sleeve 120 and the shell 101 can also cause the guide sleeve 120 to lock onto a portion of the syringe 205. In some implementations, the one or more tabs 123 formed by the u-shaped slot 126 through a thickness of the guide sleeve 120, for example, in the cylindrical underside of the guide sleeve 120 (see
As mentioned previously, the guide sleeve 120 can include an inner diameter configured to receive the outer diameter of the syringe 205 such that the syringe 205 can be inserted through the guide sleeve 120 to inject drug into the implant 110 mounted within the implant holder 125 located distal to the guide sleeve 120 (see
As mentioned above, an implant holder 125 can be removably attached within at least a region of the central channel 103 of the shell 101. The implant holder 125 can be positioned such that an interior 901 of the implant holder 125 is coaxial with the central channel 103 of the carrier member 105 and the guide sleeve 120 (see
Now with respect to
Still with respect to
The syringe needle 211 can be inserted coaxially along the axis A of the implant 110 such that the needle 211 of the syringe 205 is advanced along the axis A toward the proximal end of the implant 110. The needle 211 of the syringe 205 can penetrate the fill port until a needle stop 212 contacts the proximal surface 910 of the graspers 905 or a proximal end of the implant 110 preventing further penetration of the needle 211. The interior 901 of the implant holder 125 as well as the guide sleeve 120 can further aid in aligning the syringe 205 and the needle 211 with the implant 110 and with the longitudinal axis A. The implant holder 125 can additionally incorporate an opening into the interior 901 such that a needle can be inserted at an angle to the longitudinal axis A.
The implant holder 125 can be an interchangeable element that can lock in an alternating fashion with different portions of the system 100, such as the shell 101 of the carrier 105 and a portion of the handle member 115. The proximal end 902 of the implant holder 125 can be reversibly coupled to a region of the shell 101 such as within the central channel 103 by a locking mechanism. The locking mechanism can be configured to unlock the implant holder 125 from the shell 101 and then lock the implant holder 125 onto the handle member 115 once the handle member 115 is inserted into the carrier member 105, which is described in more detail below. The implant holder 125 can be attached to the region of the shell 101 and then attached to the handle member 115 upon release from the shell 101. The locking mechanism can include an indentation 912 near a proximal end 902 of the implant holder 125 configured to receive a correspondingly shaped element 410 of the shell 101 (see
As mentioned above, the system 100 can also include the handle member 115. After the syringe 205 is removed from the carrier 105 and the guide sleeve 120 has transferred attachment from the shell 101 of the carrier 105 to the syringe 205 as shown in
The handle member 115 can include an elongated proximal portion 510 that can be grasped by a user and the distal attachment portion 130 that can releaseably attached to the implant 110 via the implant holder 125. The proximal portion 510 of the handle member 115 can be sized and shaped to be grasped by a user and can have an ergonomic shape that facilitates quick and easy positioning of the implant 110 and release of the implant 110 into the patient. The distal attachment portion 130 of the handle member 115 can be inserted into the central channel 103 of the carrier member 105 after removal of the guide sleeve 120 from the central channel 103. In this regard, the attachment portion 130 can removably attach, engage or otherwise mate with the implant holder 125 of the carrier member 105, which holds the implant 110 (see
As described above and with respect to
Now with regard to
In an implementation, the actuator 705 can include an actuator element 701 configured to pivot around a pivot pin 710 when the actuator 705 is depressed towards an upper surface 520 of the handle member 115. The actuator element 701 can also include a projection 715 extending from its lower surface 720 such that as the element 701 pivots around the pivot pin 710 the projection 715 is moved downwards such that the ramped surface 725 of the projection 715 slides along a ramped surface 1010 of the slider member 1005. This contact between the ramped surface 725 of the projection 715 against the ramped surface 1010 of the slider member 1005 can cause the slider member 1005 to move in a proximal direction against the force of the spring 730 compressing the spring 730. The slider member 1005 can have a forked region 1015 near its distal end. The attachment portion 130 of the handle member 115 can interface with the forked region 1015. The attachment portion 130 can include a first arm 525 rotatably coupled to a second arm 530 around a pivot point 535. The first arm 525 and second arm 530 can be biased such as by a spring or other element such that their distal ends 540 are urged towards one another. As described above, the distal region 540 of the arms 525, 530 can extend within the interior 901 of the implant holder 125 such that the projections 918 of the implant holder 125 mate with the recesses 505 on the arms 525, 530. A region 545 of the arms 525, 530 proximal of the pivot point 535 can interface with the forked region 1015 of the slider member 1005. A first prong 1020a of the forked region 1015 can rest against a first region 550 of the arm 525 and a second prong 1020b of the forked region 1015 can rest against a second region 550 of the arm 530 (see
The actuator element 701 can be arranged relative to the arms 525, 530 of the handle member 115 such that as the actuator element 701 is pressed downwards towards the upper surface of the handle member 115, the arms 525, 530 can each move outward at an angle away from the longitudinal axis A of the system 100 and from one another. The arms 525, 530 can be configured to move away from one another such that one arm moves to a first side and the opposing arm moves to a second opposite side away from the longitudinal axis A of the system 100. The arms 525, 530 also can be configured to move away from one another such that one arm moves upwards and one arm moves downwards away from the longitudinal axis A of the system 100. As mentioned previously, reference herein to terms such as “upper,” “lower,” “upwards,” “downwards,” “front,” “back,” “proximal,” “distal” etc. are used herein for orientation from one point of view of a user operating the systems described herein and are not intended to be limiting. For example, the actuator element 701 can be positioned on an upper surface of the handle member 115 from the point of view of the user such that the actuator element 701 is pressed using a thumb and the actuator element 701 moved towards the upper surface of the handle member 115. The actuator element 701 also can be positioned on a lower surface of the handle member 115 from the point of view of the user such that the actuator element 701 is pressed using a finger and the actuator element 701 moved towards the lower surface of the handle member 115.
One or more components of the system 100 can be provided as a kit. The kit can include sterile packaging within which one or more components of the system 100 can be contained including the carrier member 105 having a guide sleeve 120 and implant holder 125 attached. An implant 110 can be held within the implant holder 125 or the implant 110 can be contained within sterile packaging separated from the system 100 such that the implant 110 is engaged with the implant holder 125 after the sterile kit has been opened. The kit can further include a handle member 115. The kit can further include needle assembly 210 configured to couple to a pre-filled syringe. Alternatively, the kit can include the syringe. The kit can further include a removal tool. In some implementations, the kit can include a carrier member 105 having a guide sleeve 120 and having an implant holder 125 coupled to the shell 101 of the carrier member 105. The implant holder 125 can be reversibly coupled to an implant 110. The implant 110 can be empty. In an interrelated implementation, the kit can further include a handle member 115 configured to engage with the implant holder 125 holding the implant 110 after the implant 110 has been filed with a drug. In an interrelated implementation, a syringe 205 can be provided that is configured to interdigitate with a portion of a carrier member 105 such that a needle of the syringe 205 can insert through a proximal portion of the implant 110 being held by the carrier member 105 to fill the implant 110 with a drug. The syringe 205 can be pre-filled with one or more therapeutic agents. The carrier member 105 can include a guide sleeve 120 configured to lock onto a portion of the syringe 205 upon insertion of the syringe 205 into the guide sleeve 120 of the carrier member 105. The implant 110 can be held by an implant holder 125 locked onto the carrier member 105, such as within the central channel 103. The implant holder 125 holding the implant 110 can attach to a portion of a handle member 115 after removal of the syringe 205 from the carrier member 105 upon filling of the implant 110. The handle member 115 having the implant holder 125 now attached to it can be used to deliver the implant 110 held within the implant holder 125 into a target location of the patient. In an interrelated implementation, the kit can include a carrier member 105 having a shell 101 and a guide sleeve 120, and an implant holder 125 holding an implant 110. The carrier member 105 can have a central channel 103 that facilitates access to the implant 110 being held by the implant holder 125, such as for filling with a syringe 205. The syringe 205 can be part of the kit or a separate component. The syringe 205 can be pre-filled with one or more therapeutic agents or can be empty. The handle member 115 can also be part of the kit or a separate component. The implant 110 can be part of the kit or a separate component. In an interrelated aspect, all of the components can be provided as a single kit or can be provided as separate components.
While this specification contains many specifics, these should not be construed as limitations on the scope of what is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results. Only a few examples and implementations are disclosed. Variations, modifications and enhancements to the described examples and implementations and other implementations may be made based on what is disclosed.
In the descriptions above and in the claims, phrases such as “at least one of” or “one or more of” may occur followed by a conjunctive list of elements or features. The term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features. For example, the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation is also intended for lists including three or more items. For example, the phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.”
Use of the term “based on,” above and in the claims is intended to mean, “based at least in part on,” such that an unrecited feature or element is also permissible.
This application claims priority under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 62/024,682, filed Jul. 15, 2014. The disclosure of the provisional patent application is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2564977 | Hu | Aug 1951 | A |
2585815 | McLintock | Feb 1952 | A |
3232117 | Gilmont | Feb 1966 | A |
3416530 | Ness | Dec 1968 | A |
3618604 | Ness | Nov 1971 | A |
3641237 | Gould et al. | Feb 1972 | A |
3828777 | Ness | Aug 1974 | A |
3902495 | Weiss et al. | Sep 1975 | A |
3916899 | Theeuwes et al. | Nov 1975 | A |
3949748 | Malmin | Apr 1976 | A |
3949750 | Freeman | Apr 1976 | A |
3961628 | Arnold | Jun 1976 | A |
3977404 | Theeuwes | Aug 1976 | A |
3995635 | Higuchi et al. | Dec 1976 | A |
4008719 | Theeuwes et al. | Feb 1977 | A |
4014333 | McIntyre | Mar 1977 | A |
4014334 | Theeuwes et al. | Mar 1977 | A |
4014335 | Arnold | Mar 1977 | A |
4034756 | Higuchi et al. | Jul 1977 | A |
4034758 | Theeuwes | Jul 1977 | A |
4077407 | Theeuwes et al. | Mar 1978 | A |
4111201 | Theeuwes | Sep 1978 | A |
4111203 | Theeuwes | Sep 1978 | A |
4135514 | Zaffaroni et al. | Jan 1979 | A |
4160452 | Theeuwes | Jul 1979 | A |
4200098 | Ayer et al. | Apr 1980 | A |
4220152 | Dresback | Sep 1980 | A |
4220153 | Dresback | Sep 1980 | A |
4256108 | Theeuwes | Mar 1981 | A |
4298000 | Thill et al. | Nov 1981 | A |
4300557 | Refojo et al. | Nov 1981 | A |
4309776 | Berguer | Jan 1982 | A |
4326525 | Swanson et al. | Apr 1982 | A |
4327725 | Cortese et al. | May 1982 | A |
4439196 | Higuchi | Mar 1984 | A |
4475916 | Himmelstein | Oct 1984 | A |
4484922 | Rosenwald | Nov 1984 | A |
4519801 | Edgren | May 1985 | A |
4609374 | Ayer | Sep 1986 | A |
4627850 | Deters et al. | Dec 1986 | A |
4673405 | Guittard et al. | Jun 1987 | A |
4693886 | Ayer | Sep 1987 | A |
4712550 | Sinnett | Dec 1987 | A |
4737150 | Baeumle et al. | Apr 1988 | A |
4777049 | Magruder et al. | Oct 1988 | A |
4781675 | White | Nov 1988 | A |
4863457 | Lee | Sep 1989 | A |
4865846 | Kaufman | Sep 1989 | A |
4883459 | Calderon | Nov 1989 | A |
4959217 | Sanders et al. | Sep 1990 | A |
5084021 | Baldwin | Jan 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5128145 | Edgren et al. | Jul 1992 | A |
5164188 | Wong | Nov 1992 | A |
5174999 | Magruder et al. | Dec 1992 | A |
5178622 | Lehner, II | Jan 1993 | A |
5277912 | Lowe et al. | Jan 1994 | A |
5282829 | Hermes | Feb 1994 | A |
5300114 | Gwon et al. | Apr 1994 | A |
5322691 | Darougar et al. | Jun 1994 | A |
5334189 | Wade | Aug 1994 | A |
5336175 | Mames | Aug 1994 | A |
5378475 | Smith et al. | Jan 1995 | A |
5413572 | Wong et al. | May 1995 | A |
5443505 | Wong et al. | Aug 1995 | A |
5476511 | Gwon et al. | Dec 1995 | A |
5516522 | Peyman et al. | May 1996 | A |
5554132 | Straits et al. | Sep 1996 | A |
5562915 | Lowe et al. | Oct 1996 | A |
5681572 | Seare, Jr. | Oct 1997 | A |
5702414 | Richter et al. | Dec 1997 | A |
5766242 | Wong et al. | Jun 1998 | A |
5770076 | Chu et al. | Jun 1998 | A |
5773019 | Ashton et al. | Jun 1998 | A |
5797898 | Santini, Jr. et al. | Aug 1998 | A |
5807581 | Rosenblatt et al. | Sep 1998 | A |
5824072 | Wong | Oct 1998 | A |
5830173 | Avery et al. | Nov 1998 | A |
5830546 | Ehret et al. | Nov 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
5868697 | Richter et al. | Feb 1999 | A |
5902598 | Chen et al. | May 1999 | A |
5916584 | O'Donoghue et al. | Jun 1999 | A |
5928662 | Phillips | Jul 1999 | A |
5951512 | Dalton | Sep 1999 | A |
5972369 | Roorda et al. | Oct 1999 | A |
5985328 | Chu et al. | Nov 1999 | A |
6001386 | Ashton et al. | Dec 1999 | A |
6039712 | Fogarty et al. | Mar 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6123861 | Santini, Jr. et al. | Sep 2000 | A |
6196993 | Cohan et al. | Mar 2001 | B1 |
6303290 | Liu et al. | Oct 2001 | B1 |
6331313 | Wong et al. | Dec 2001 | B1 |
6375972 | Guo et al. | Apr 2002 | B1 |
6395300 | Straub et al. | May 2002 | B1 |
6413540 | Yaacobi | Jul 2002 | B1 |
6416777 | Yaacobi | Jul 2002 | B1 |
6420399 | Graff et al. | Jul 2002 | B1 |
6472162 | Coelho et al. | Oct 2002 | B1 |
6605066 | Gravagna et al. | Aug 2003 | B1 |
6663668 | Chaouk et al. | Dec 2003 | B1 |
6669950 | Yaacobi | Dec 2003 | B2 |
6685940 | Andya et al. | Feb 2004 | B2 |
6713081 | Robinson et al. | Mar 2004 | B2 |
6719750 | Varner et al. | Apr 2004 | B2 |
6740077 | Brandau et al. | May 2004 | B1 |
6756049 | Brubaker et al. | Jun 2004 | B2 |
6756058 | Brubaker et al. | Jun 2004 | B2 |
6932983 | Straub et al. | Aug 2005 | B1 |
6976982 | Santini, Jr. et al. | Dec 2005 | B2 |
6986900 | Yaacobi | Jan 2006 | B2 |
7026329 | Crain et al. | Apr 2006 | B2 |
7074426 | Kochinke | Jul 2006 | B2 |
7077848 | de Juan, Jr. et al. | Jul 2006 | B1 |
7090681 | Weber et al. | Aug 2006 | B2 |
7094226 | Yaacobi | Aug 2006 | B2 |
7117870 | Prescott | Oct 2006 | B2 |
7141152 | Le Febre | Nov 2006 | B2 |
7181287 | Greenberg | Feb 2007 | B2 |
7195774 | Carvalho et al. | Mar 2007 | B2 |
7195778 | Fleshner-Barak et al. | Mar 2007 | B2 |
7211272 | Renner et al. | May 2007 | B2 |
7252673 | Lim | Aug 2007 | B2 |
7276050 | Franklin | Oct 2007 | B2 |
7468065 | Weber et al. | Dec 2008 | B2 |
7476510 | Kapur et al. | Jan 2009 | B2 |
7585517 | Cooper et al. | Sep 2009 | B2 |
7615141 | Schwartz et al. | Nov 2009 | B2 |
7621907 | Rodstrom | Nov 2009 | B2 |
7625927 | Klimko et al. | Dec 2009 | B2 |
7678078 | Peyman et al. | Mar 2010 | B1 |
7686016 | Wharton et al. | Mar 2010 | B2 |
7709049 | Chappa | May 2010 | B2 |
7753916 | Weber et al. | Jul 2010 | B2 |
7883717 | Varner et al. | Feb 2011 | B2 |
7893040 | Loftsson et al. | Feb 2011 | B2 |
7906136 | Wong et al. | Mar 2011 | B2 |
7909800 | Cazzini | Mar 2011 | B2 |
7914442 | Gazdzinski | Mar 2011 | B1 |
7939094 | Schwarz et al. | May 2011 | B2 |
7973068 | Demopulos et al. | Jul 2011 | B2 |
8313454 | Yaron et al. | Nov 2012 | B2 |
8399006 | de Juan, Jr. et al. | Mar 2013 | B2 |
8403941 | Peterson | Mar 2013 | B2 |
8623395 | de Juan, Jr. et al. | Jan 2014 | B2 |
8905963 | de Juan, Jr. et al. | Dec 2014 | B2 |
9987163 | Schaller | Jun 2018 | B2 |
20020026176 | Varner et al. | Feb 2002 | A1 |
20020086051 | Viscasillas | Jul 2002 | A1 |
20020106395 | Brubaker | Aug 2002 | A1 |
20020110591 | Brubaker et al. | Aug 2002 | A1 |
20020110592 | Brubaker et al. | Aug 2002 | A1 |
20020110635 | Brubaker et al. | Aug 2002 | A1 |
20020116009 | Fraser et al. | Aug 2002 | A1 |
20020133168 | Smedley et al. | Sep 2002 | A1 |
20030003129 | Yaacobi | Jan 2003 | A1 |
20030005945 | Onishi et al. | Jan 2003 | A1 |
20030014036 | Varner et al. | Jan 2003 | A1 |
20030118649 | Gao et al. | Jun 2003 | A1 |
20030119177 | Gruber et al. | Jun 2003 | A1 |
20030176854 | Rodstrom | Sep 2003 | A1 |
20030185872 | Kochinke | Oct 2003 | A1 |
20030212383 | Cote et al. | Nov 2003 | A1 |
20030235603 | Schwarz et al. | Dec 2003 | A1 |
20040011651 | Becker et al. | Jan 2004 | A1 |
20040019325 | Shekalim | Jan 2004 | A1 |
20040092911 | Yaacobi | May 2004 | A1 |
20040106906 | Yaacobi | Jun 2004 | A1 |
20040131654 | Yaacobi | Jul 2004 | A1 |
20040131655 | Yaacobi | Jul 2004 | A1 |
20040209359 | Yayon et al. | Oct 2004 | A1 |
20040230183 | Breegi et al. | Nov 2004 | A1 |
20040238392 | Peterson et al. | Dec 2004 | A1 |
20040260380 | Marco et al. | Dec 2004 | A1 |
20040260381 | Marco et al. | Dec 2004 | A1 |
20050055031 | Lim | Mar 2005 | A1 |
20050064010 | Cooper et al. | Mar 2005 | A1 |
20050074497 | Schultz | Apr 2005 | A1 |
20050112175 | Yaacobi | May 2005 | A1 |
20050112759 | Radisic et al. | May 2005 | A1 |
20050113806 | De Carvalho et al. | May 2005 | A1 |
20050119737 | Bene et al. | Jun 2005 | A1 |
20050143363 | De Juan et al. | Jun 2005 | A1 |
20050154399 | Weber et al. | Jul 2005 | A1 |
20050163711 | Nycz et al. | Jul 2005 | A1 |
20050181018 | Peyman | Aug 2005 | A1 |
20050244467 | Nivaggioli et al. | Nov 2005 | A1 |
20050244469 | Whitcup et al. | Nov 2005 | A1 |
20050255144 | Schultz | Nov 2005 | A1 |
20050256499 | Pettis et al. | Nov 2005 | A1 |
20050271703 | Anderson et al. | Dec 2005 | A1 |
20050271706 | Anderson et al. | Dec 2005 | A1 |
20050276837 | Anderson et al. | Dec 2005 | A1 |
20050277802 | Larsen et al. | Dec 2005 | A1 |
20050281861 | Hughes et al. | Dec 2005 | A1 |
20050281863 | Anderson et al. | Dec 2005 | A1 |
20050287188 | Anderson et al. | Dec 2005 | A1 |
20060013835 | Anderson et al. | Jan 2006 | A1 |
20060039952 | Yaacobi | Feb 2006 | A1 |
20060052754 | Fields | Mar 2006 | A1 |
20060057277 | Chappa | Mar 2006 | A1 |
20060073182 | Wong et al. | Apr 2006 | A1 |
20060104969 | Oray et al. | May 2006 | A1 |
20060110428 | deJuan et al. | May 2006 | A1 |
20060129215 | Helmus et al. | Jun 2006 | A1 |
20060154981 | Klimko et al. | Jul 2006 | A1 |
20060172941 | Rastelli et al. | Aug 2006 | A1 |
20060182783 | Hughes et al. | Aug 2006 | A1 |
20060200097 | Humayun et al. | Sep 2006 | A1 |
20060233858 | Tzekov et al. | Oct 2006 | A1 |
20060246112 | Snyder et al. | Nov 2006 | A1 |
20060257450 | Mudumba et al. | Nov 2006 | A1 |
20060258000 | Allen et al. | Nov 2006 | A1 |
20060258994 | Avery | Nov 2006 | A1 |
20060276738 | Becker | Dec 2006 | A1 |
20070020336 | Loftsson et al. | Jan 2007 | A1 |
20070021357 | Tobia et al. | Jan 2007 | A1 |
20070026037 | Kloke et al. | Feb 2007 | A1 |
20070059336 | Hughes et al. | Mar 2007 | A1 |
20070071756 | Peyman | Mar 2007 | A1 |
20070072933 | Peyman | Mar 2007 | A1 |
20070077270 | Wen | Apr 2007 | A1 |
20070088414 | Campbell et al. | Apr 2007 | A1 |
20070119450 | Wharton et al. | May 2007 | A1 |
20070128644 | Munenaka | Jun 2007 | A1 |
20070131610 | Peng et al. | Jun 2007 | A1 |
20070131611 | Peng et al. | Jun 2007 | A1 |
20070134305 | Zilberman | Jun 2007 | A1 |
20070141111 | Suokas et al. | Jun 2007 | A1 |
20070191863 | De Juan et al. | Aug 2007 | A1 |
20070197491 | Robin et al. | Aug 2007 | A1 |
20070203174 | Klimko et al. | Aug 2007 | A1 |
20070212397 | Roth | Sep 2007 | A1 |
20070233037 | Gifford et al. | Oct 2007 | A1 |
20070235331 | Simpson et al. | Oct 2007 | A1 |
20070243230 | de Juan et al. | Oct 2007 | A1 |
20070260201 | Prausnitz et al. | Nov 2007 | A1 |
20070269487 | de Juan et al. | Nov 2007 | A1 |
20080003219 | Peyman | Jan 2008 | A1 |
20080004329 | Jamieson et al. | Jan 2008 | A1 |
20080020045 | Chappa et al. | Jan 2008 | A1 |
20080038316 | Wong et al. | Feb 2008 | A1 |
20080057561 | Takahashi et al. | Mar 2008 | A1 |
20080066739 | LeMahieu et al. | Mar 2008 | A1 |
20080066741 | LeMahieu et al. | Mar 2008 | A1 |
20080069854 | Xiao et al. | Mar 2008 | A1 |
20080089923 | Burkstrand et al. | Apr 2008 | A1 |
20080097459 | Kammerlander | Apr 2008 | A1 |
20080111282 | Xie et al. | May 2008 | A1 |
20080124372 | Hossainy et al. | May 2008 | A1 |
20080139674 | Archambeau et al. | Jun 2008 | A1 |
20080145406 | Asgharian et al. | Jun 2008 | A1 |
20080146679 | Archambeau et al. | Jun 2008 | A1 |
20080147021 | Jani | Jun 2008 | A1 |
20080152694 | Lobl et al. | Jun 2008 | A1 |
20080154241 | Burkstrand et al. | Jun 2008 | A1 |
20080161741 | Bene et al. | Jul 2008 | A1 |
20080167600 | Peyman | Jul 2008 | A1 |
20080172014 | Whitcup et al. | Jul 2008 | A1 |
20080181930 | Rodstrom et al. | Jul 2008 | A1 |
20080200922 | Brown | Aug 2008 | A1 |
20080207502 | Rastelli et al. | Aug 2008 | A1 |
20080213611 | Asgari | Sep 2008 | A1 |
20080216736 | David | Sep 2008 | A1 |
20080228127 | Burns et al. | Sep 2008 | A1 |
20080233053 | Gross et al. | Sep 2008 | A1 |
20080233171 | Whitcup et al. | Sep 2008 | A1 |
20080233172 | Whitcup et al. | Sep 2008 | A1 |
20080233173 | Whitcup et al. | Sep 2008 | A1 |
20080241219 | Whitcup et al. | Oct 2008 | A1 |
20080241220 | Whitcup et al. | Oct 2008 | A1 |
20080241221 | Whitcup et al. | Oct 2008 | A1 |
20080241222 | Whitcup et al. | Oct 2008 | A1 |
20080241223 | Nivaggioli et al. | Oct 2008 | A1 |
20080249501 | Yamasaki | Oct 2008 | A1 |
20080286338 | Rosenthal et al. | Nov 2008 | A1 |
20080292679 | Lyons et al. | Nov 2008 | A1 |
20090005864 | Eggleston | Jan 2009 | A1 |
20090036827 | Cazzini | Feb 2009 | A1 |
20090043253 | Podaima | Feb 2009 | A1 |
20090047335 | Rastelli et al. | Feb 2009 | A1 |
20090082631 | Cronin et al. | Mar 2009 | A1 |
20090087494 | Kompella et al. | Apr 2009 | A1 |
20090092654 | de Juan, Jr. et al. | Apr 2009 | A1 |
20090093752 | Richard et al. | Apr 2009 | A1 |
20090099626 | de Juan, Jr. et al. | Apr 2009 | A1 |
20090104243 | Utkhede et al. | Apr 2009 | A1 |
20090105749 | de Juan et al. | Apr 2009 | A1 |
20090124997 | Pettis et al. | May 2009 | A1 |
20090214601 | Chappa et al. | Aug 2009 | A1 |
20090224064 | Brodbeck et al. | Sep 2009 | A1 |
20090234449 | De Juan, Jr. et al. | Sep 2009 | A1 |
20090240215 | Humayun et al. | Sep 2009 | A1 |
20090247458 | Watson et al. | Oct 2009 | A1 |
20090258069 | Burnier et al. | Oct 2009 | A1 |
20090263346 | Taft et al. | Oct 2009 | A1 |
20090263495 | Watson et al. | Oct 2009 | A1 |
20090274730 | Watson et al. | Nov 2009 | A1 |
20090274771 | Watson et al. | Nov 2009 | A1 |
20090280470 | Fare et al. | Nov 2009 | A1 |
20090281621 | Becker | Nov 2009 | A1 |
20090324686 | Cooper et al. | Dec 2009 | A1 |
20090324687 | Cooper et al. | Dec 2009 | A1 |
20090324688 | Cooper et al. | Dec 2009 | A1 |
20090324689 | Cooper et al. | Dec 2009 | A1 |
20090324690 | Cooper et al. | Dec 2009 | A1 |
20090326448 | Huo et al. | Dec 2009 | A1 |
20100003333 | Watson et al. | Jan 2010 | A1 |
20100004189 | Watson et al. | Jan 2010 | A1 |
20100008997 | Watson et al. | Jan 2010 | A1 |
20100009008 | Watson et al. | Jan 2010 | A1 |
20100010452 | Paques et al. | Jan 2010 | A1 |
20100011888 | Pawliszyn et al. | Jan 2010 | A1 |
20100015157 | Andya et al. | Jan 2010 | A1 |
20100016786 | Drews et al. | Jan 2010 | A1 |
20100021464 | Archambeau et al. | Jan 2010 | A1 |
20100022943 | Mauch et al. | Jan 2010 | A1 |
20100022945 | Rodstrom | Jan 2010 | A1 |
20100023033 | Mauch et al. | Jan 2010 | A1 |
20100028442 | Archambeau et al. | Feb 2010 | A1 |
20100028443 | Watson et al. | Feb 2010 | A1 |
20100030136 | Dacquay et al. | Feb 2010 | A1 |
20100034870 | Sim et al. | Feb 2010 | A1 |
20100083963 | Wharton et al. | Apr 2010 | A1 |
20100100054 | Cormier et al. | Apr 2010 | A1 |
20100100104 | Yu et al. | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100114309 | de Juan, Jr. et al. | May 2010 | A1 |
20100168535 | Robinson et al. | Jul 2010 | A1 |
20100174272 | Weiner | Jul 2010 | A1 |
20100185205 | Novakovic et al. | Jul 2010 | A1 |
20100197512 | Trinkle et al. | Aug 2010 | A1 |
20100216702 | Szkudlinski et al. | Aug 2010 | A1 |
20100221309 | Myers et al. | Sep 2010 | A1 |
20100241102 | Ma | Sep 2010 | A1 |
20100255061 | de Juan, Jr. et al. | Oct 2010 | A1 |
20100256597 | Prausnitz et al. | Oct 2010 | A1 |
20100266664 | Asgharian et al. | Oct 2010 | A1 |
20100286121 | Rohrs et al. | Nov 2010 | A1 |
20100286791 | Goldsmith | Nov 2010 | A1 |
20100297046 | Schwartz et al. | Nov 2010 | A1 |
20100297120 | Beliveau et al. | Nov 2010 | A1 |
20100297193 | Archambeau et al. | Nov 2010 | A1 |
20100303917 | Watson et al. | Dec 2010 | A1 |
20100303918 | Watson et al. | Dec 2010 | A1 |
20100310664 | Watson et al. | Dec 2010 | A1 |
20100310665 | Watson et al. | Dec 2010 | A1 |
20100316723 | Watson et al. | Dec 2010 | A1 |
20100330146 | Chauhan et al. | Dec 2010 | A1 |
20110009571 | Taft et al. | Jan 2011 | A1 |
20110014264 | Helmus et al. | Jan 2011 | A1 |
20110033933 | Gharib et al. | Feb 2011 | A1 |
20110034448 | Chang et al. | Feb 2011 | A1 |
20110081384 | Archambeau et al. | Apr 2011 | A1 |
20110098686 | Varner et al. | Apr 2011 | A1 |
20110104155 | Rekik | May 2011 | A1 |
20110108025 | Fink et al. | May 2011 | A1 |
20110111006 | Wong et al. | May 2011 | A1 |
20110112188 | Tobia et al. | May 2011 | A1 |
20110117083 | Bais et al. | May 2011 | A1 |
20110125178 | Drews et al. | May 2011 | A1 |
20110159073 | deJuan et al. | Jun 2011 | A1 |
20110196317 | Lust et al. | Aug 2011 | A1 |
20110206646 | Alfonso et al. | Aug 2011 | A1 |
20120029445 | de Juan, Jr. et al. | Feb 2012 | A1 |
20120029470 | de Juan, Jr. et al. | Feb 2012 | A1 |
20120245505 | Robinson et al. | Sep 2012 | A1 |
20130204209 | de Juan, Jr. et al. | Aug 2013 | A1 |
20130218081 | Roth | Aug 2013 | A1 |
20130274691 | de Juan, Jr. et al. | Oct 2013 | A1 |
20130274692 | Alster et al. | Oct 2013 | A1 |
20130324918 | de Juan, Jr. et al. | Dec 2013 | A1 |
20130324942 | de Juan, Jr. et al. | Dec 2013 | A1 |
20140031769 | de Juan, Jr. et al. | Jan 2014 | A1 |
20140033800 | Farinas et al. | Feb 2014 | A1 |
20140073714 | Reich et al. | Mar 2014 | A1 |
20140114323 | Kudo | Apr 2014 | A1 |
20140121609 | de Juan, Jr. et al. | May 2014 | A1 |
20140221941 | Erickson et al. | Aug 2014 | A1 |
20140243795 | Varner et al. | Aug 2014 | A1 |
20140276482 | Astafieva et al. | Sep 2014 | A1 |
20140276901 | Auld | Sep 2014 | A1 |
20140296800 | Erickson et al. | Oct 2014 | A1 |
20140303637 | Downer | Oct 2014 | A1 |
20140326249 | Cappiello et al. | Nov 2014 | A1 |
20140358125 | de Juan, Jr. et al. | Dec 2014 | A1 |
20140379079 | Ben Nun | Dec 2014 | A1 |
20150045805 | Kontur et al. | Feb 2015 | A1 |
20150080846 | de Juan, Jr. et al. | Mar 2015 | A1 |
20150250647 | de Juan, Jr. et al. | Sep 2015 | A1 |
20150297402 | de Juan, Jr. et al. | Oct 2015 | A1 |
20160038488 | Horvath et al. | Feb 2016 | A1 |
20160101046 | Reich et al. | Apr 2016 | A1 |
20160128867 | Bachelder et al. | May 2016 | A1 |
20160184134 | Varner et al. | Jun 2016 | A1 |
20160258855 | Farinas et al. | Sep 2016 | A1 |
20160302965 | Erickson et al. | Oct 2016 | A1 |
20170165108 | Bianchi et al. | Jun 2017 | A1 |
20170165110 | Erickson et al. | Jun 2017 | A1 |
20170172794 | Varner et al. | Jun 2017 | A1 |
20170258634 | de Juan, Jr. et al. | Sep 2017 | A1 |
20180147204 | Horvath et al. | May 2018 | A1 |
20180161202 | de Juan, Jr. et al. | Jun 2018 | A1 |
20180243130 | Doud et al. | Aug 2018 | A1 |
20180243131 | Erickson et al. | Aug 2018 | A1 |
20180289542 | de Juan, Jr. et al. | Oct 2018 | A1 |
20180292403 | de Juan, Jr. et al. | Oct 2018 | A1 |
20190117454 | Campbell et al. | Apr 2019 | A1 |
20190336335 | de Juan, Jr. et al. | Nov 2019 | A1 |
20190365757 | Horvath et al. | Dec 2019 | A1 |
20200030142 | Erickson et al. | Jan 2020 | A1 |
20200060874 | Bachelder et al. | Feb 2020 | A1 |
20200107955 | Erickson et al. | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
2015289625 | Oct 2019 | AU |
102098993 | Jun 2011 | CN |
102365109 | Feb 2012 | CN |
0228185 | Jul 1990 | EP |
0498471 | Aug 1992 | EP |
0500143 | Aug 1992 | EP |
0671165 | Sep 1995 | EP |
0295248 | Apr 1999 | EP |
0944658 | Jun 2003 | EP |
1671624 | Jun 2006 | EP |
1385452 | Sep 2006 | EP |
1409065 | Jan 2007 | EP |
1337284 | Dec 2007 | EP |
1911481 | Apr 2008 | EP |
1521572 | Mar 2009 | EP |
3169289 | Apr 2020 | EP |
3679908 | Jul 2020 | EP |
2004525695 | Aug 2004 | JP |
2006526462 | Nov 2006 | JP |
2387462 | Apr 2010 | RU |
WO-8804573 | Jun 1988 | WO |
WO-9007545 | Jul 1990 | WO |
WO-9528984 | Nov 1995 | WO |
WO-9729850 | Aug 1997 | WO |
WO-9825982 | Jun 1998 | WO |
WO-0048660 | Aug 2000 | WO |
WO-0126714 | Apr 2001 | WO |
WO-0150943 | Jul 2001 | WO |
WO-03077972 | Sep 2003 | WO |
WO-03082188 | Oct 2003 | WO |
WO-2004000267 | Dec 2003 | WO |
WO-2004112653 | Dec 2004 | WO |
WO-2005016401 | Feb 2005 | WO |
WO-2005027906 | Mar 2005 | WO |
WO-2005028006 | Mar 2005 | WO |
WO-2005091922 | Oct 2005 | WO |
WO-2005107705 | Nov 2005 | WO |
WO-2005110362 | Nov 2005 | WO |
WO-2005110436 | Nov 2005 | WO |
WO-2005110473 | Nov 2005 | WO |
WO-2005117780 | Dec 2005 | WO |
WO-2006014484 | Feb 2006 | WO |
WO-2006015385 | Feb 2006 | WO |
WO-2006023530 | Mar 2006 | WO |
WO-2006031358 | Mar 2006 | WO |
WO-2006031388 | Mar 2006 | WO |
WO-2006044614 | Apr 2006 | WO |
WO-2006068838 | Jun 2006 | WO |
WO-2006071554 | Jul 2006 | WO |
WO-2006082588 | Aug 2006 | WO |
WO-2006108054 | Oct 2006 | WO |
WO-2006125106 | Nov 2006 | WO |
WO-2006127962 | Nov 2006 | WO |
WO-2006138609 | Dec 2006 | WO |
WO-2007012974 | Feb 2007 | WO |
WO-2007035621 | Mar 2007 | WO |
WO-2007038453 | Apr 2007 | WO |
WO-2007044534 | Apr 2007 | WO |
WO-2007047744 | Apr 2007 | WO |
WO-2007066339 | Jun 2007 | WO |
WO-2007084582 | Jul 2007 | WO |
WO-2007084765 | Jul 2007 | WO |
WO-2007101204 | Sep 2007 | WO |
WO-2007117394 | Oct 2007 | WO |
WO-2007131050 | Nov 2007 | WO |
WO-2007133761 | Nov 2007 | WO |
WO-2007133762 | Nov 2007 | WO |
WO-2008003043 | Jan 2008 | WO |
WO-2008005240 | Jan 2008 | WO |
WO-2008011125 | Jan 2008 | WO |
WO-2008019265 | Feb 2008 | WO |
WO-2008033924 | Mar 2008 | WO |
WO-2008040062 | Apr 2008 | WO |
WO-2008045272 | Apr 2008 | WO |
WO-2008052145 | May 2008 | WO |
WO-2008060359 | May 2008 | WO |
WO-2008061043 | May 2008 | WO |
WO-2008076544 | Jun 2008 | WO |
WO-2008084063 | Jul 2008 | WO |
WO-2008094989 | Aug 2008 | WO |
WO-2008115290 | Sep 2008 | WO |
WO-2008116165 | Sep 2008 | WO |
WO-2008144340 | Nov 2008 | WO |
WO-2008144919 | Dec 2008 | WO |
WO-2009012075 | Jan 2009 | WO |
WO-2009023615 | Feb 2009 | WO |
WO-2009046164 | Apr 2009 | WO |
WO-2009055620 | Apr 2009 | WO |
WO-2009055671 | Apr 2009 | WO |
WO-2009055729 | Apr 2009 | WO |
WO-2009055824 | Apr 2009 | WO |
WO-2009061607 | May 2009 | WO |
WO-2009073192 | Jun 2009 | WO |
WO-2009086112 | Jul 2009 | WO |
WO-2009089409 | Jul 2009 | WO |
WO-2009094466 | Jul 2009 | WO |
WO-2009112878 | Sep 2009 | WO |
WO-2009117112 | Sep 2009 | WO |
WO-2009124096 | Oct 2009 | WO |
WO-2009128932 | Oct 2009 | WO |
WO-2009134929 | Nov 2009 | WO |
WO-2009137777 | Nov 2009 | WO |
WO-2010008424 | Jan 2010 | WO |
WO-2010021993 | Feb 2010 | WO |
WO-2010047753 | Apr 2010 | WO |
WO-2010062628 | Jun 2010 | WO |
WO-2010066714 | Jun 2010 | WO |
WO-2010075565 | Jul 2010 | WO |
WO-2010078063 | Jul 2010 | WO |
WO-2010080987 | Jul 2010 | WO |
WO-2010088548 | Aug 2010 | WO |
WO-2010093945 | Aug 2010 | WO |
WO-2010095940 | Aug 2010 | WO |
WO-2010125416 | Nov 2010 | WO |
WO-2010126908 | Nov 2010 | WO |
WO-2010135369 | Nov 2010 | WO |
WO-2010141729 | Dec 2010 | WO |
WO-2010147661 | Dec 2010 | WO |
WO-2011008896 | Jan 2011 | WO |
WO-2011008897 | Jan 2011 | WO |
WO-2011028850 | Mar 2011 | WO |
WO-2011034627 | Mar 2011 | WO |
2011075481 | Jun 2011 | WO |
WO-2011079232 | Jun 2011 | WO |
WO-2012019136 | Feb 2012 | WO |
WO-2013082452 | Jun 2013 | WO |
WO-2013116061 | Aug 2013 | WO |
2013184727 | Dec 2013 | WO |
2014165345 | Oct 2014 | WO |
2016011191 | Jan 2016 | WO |
WO-2017087902 | May 2017 | WO |
Entry |
---|
Andrews, “Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa,” Am J Physiol. Apr. 1994; 266(4 Pt 1):G657-664. |
Avery et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology. Oct. 2006, 113(10):1695-1705.e6. |
Bakri et al., “The effect of intravitreal triamcinolone acetonide on intraocular pressure,” Ophthalmic Surgery, Lasers and Imaging, Sep./Oct. 2003;34(5): 386-390. |
Bird et al., Transport Phenomena, John Wiley & Sons, Inc., New York, 1960, pp. 196-201. |
Block et al., “Solubility and dissolution of triamcinolone acetonide,” Journal of Pharmaceutical Sciences, Apr. 1973; 62(4):617-621. |
Castro et al., “Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization,” Exp Eye Res. Aug. 2004;79(2):275-285. |
Chirila et al., “The Vitreous Humor” in Handbook of Biomaterial Properties, eds. Black & Hastings. Chapman & Hall, London, 1998; pp. 125-131. |
Cousins et al., “Program# 1251—Targeting Complement Factors 5 in Combination with Vascular Endothelial Growth Factor (VEGF) Inhibition for Neovascular Age Related Macular Degeneration (AMD): Results of a Phase 1 Study,” [Presentation Abstract], AMD Clinical Trials Session # 220, May 3, 2010. 2 pages. |
Deissler et al., “VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells,”Br J Ophthalmol 2008;92:839-843. |
Donoso et al., “The role of inflammation in the pathogenesis of age-related macular degeneration,” Surv Ophthalmol. Mar.-Apr. 2006;51(2):137-52. |
Edelhauser, H et al. “Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases Basic Research to Clinical Applications.” Investigative Ophthalmology & Visual Science, Nov. 2010. vol. 51, No. 11. pp. 5403-5420. |
European Medicine Agency, Scientific Discussion; retrieved from the Internet; <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf>, EMEA 2007, 54 pages total. 2007. |
Funatsu et al. “Association of vitreous inflammatory factors with diabetic macular edema,” Ophthalmology 2009;116:73-79. |
Gaudreault et al., “Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration,” Investigative Ophthalmology and Visual Science. 2005;46:726-733. Retrieved from the Internet: <<http://www.iovs.org/cgi/reprint/46/2/726>>. |
Gillies et al., “Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial,” Ophthalmology. Sep. 2006;113(9):1533-1538. |
Hastedt & Wright, “Diffusion in porous materials above the percolation threshold,” Pharm. Res. Sep. 1990; 7(9):893-901 (1990). |
Heier et al., “Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema,” Ophthalmology. Nov. 2000;107(11):2034-2038; discussion 2039. |
Jena et al., “A Novel Technique for Surface Area and Particle Size Determination of Components of Fuel Cells and Batteries,” Porous Materials, Inc., Dec. 2006, 3 pages total. Downloaded from the Internet: <<http://www.pmiapp.com/publications/docs/A_Novel_technique_for_surface_area.pdf>>. |
Kang et al., “Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity,” Biol Pharm Bull. Jun. 2001;24(6):701-703. |
Lopez-Armada et al., “Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis,” Ann Rheum Dis Nov. 2002;61(11):1027-1030. |
Luncentis, INN-Ranibizumab, “Scientific Discussion,” European Medicines Agency ; retrieved from the Internet:<http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000715/WC500101009.pdf>. Oct. 21, 2010. 32 pages. |
Metal Powder Industries Federation, Porous Metal Design Guidebook, 2007, 24 pages total. Downloaded from the Internet: <<http://www.mpif.org/DesignCenter/porous.pdf>>. |
MOTT Corporation, “Sintered Metal Powder Media,” American Filtration & Separation Society 2007, 2 pages total. Downloaded from the Internet:<<http://www.afssociety.org/education/0907oneminute.htm>>. |
Navarro, “The Optical Design of the Human Eye: a Critical Review,” J Optom, Jan.-Mar. 2009 2(1): 3-18. |
Okabe et al., “Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device,” Investigative Ophthalmology and Visual Science. 2003;44:2702-2707. Downloaded from the Internet: <<http://www.iovs.Org/cgi/reprint/44/6/2702>>. |
Rosenfeld, “The Latest Research: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy,” Review of Ophthalmology's Retina Online, Feb. 2006; retrieved from the Internet: http://www.revophth.com/archive/newsletter/0206_retina.htm. 2 pages. |
Smith et al., “Spectrophotometric determination of pKa values for fluorescein using activity coefficient corrections,” WaterSA 2002; 28(4):395-402. |
Soheilian et al., “Pilot Study of Intravitreal Injection of Diclofenac for Treatment of Macular Edema of Various Etiologies,” Retina, Mar. 2010; 30(3): 509-515. |
Theodossiadis et al., “Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration,” Am J Ophthalmol. May 2009;147(5):825-830. |
Williams et al., “Treating Diabetic Macular Edema With Ocular NSAIDs,” Retinal Physician, Nov. 2007; retrieved from the Internet Nov. 11, 2007. http://www.retinalphysician.com/article.aspx?article=101096>, 5 pages total. |
Number | Date | Country | |
---|---|---|---|
20190350754 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62024682 | Jul 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15325995 | US | |
Child | 16380786 | US |